Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202

por Ruppert, Amy S., Booth, Allison M., Ding, Wei, Bartlett, Nancy L., Brander, Danielle M., Coutre, Steven, Brown, Jennifer R., Nattam, Sreenivasa, Larson, Richard A., Erba, Harry, Litzow, Mark, Owen, Carolyn, Kuzma, Charles S., Abramson, Jeremy S., Little, Richard F., Smith, Scott E., Stone, Richard M., Byrd, John C., Mandrekar, Sumithra J., Woyach, Jennifer A.
Publicado 2021

CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Nega...

por Shepherd, Jonathan H., Ballman, Karla, Polley, Mei-Yin C., Campbell, Jordan D., Fan, Cheng, Selitsky, Sara, Fernandez-Martinez, Aranzazu, Parker, Joel S., Hoadley, Katherine A., Hu, Zhiyuan, Li, Yan, Soloway, Matthew G., Spears, Patricia A., Singh, Baljit, Tolaney, Sara M., Somlo, George, Port, Elisa R., Ma, Cynthia, Kuzma, Charles, Mamounas, Eleftherios, Golshan, Mehra, Bellon, Jennifer R., Collyar, Deborah, Hahn, Olwen M., Hudis, Clifford A., Winer, Eric P., Partridge, Ann, Hyslop, Terry, Carey, Lisa A., Perou, Charles M., Sikov, William M.
Publicado 2022